Gilead Sciences, Inc.
Gilead works to advance therapeutics for life-threatening diseases worldwide through discovering, developing, and commercializing small molecule therapeutics to advance the care of patients suffering from life-threatening infectious diseases. Gilead has a clinical, preclinical, and research pipeline focused on developing anti-infective agents. For more information about Gilead, visit: http://www.gilead.com/wt/home.
Idenix Pharmaceuticals, Inc.
Idenix is engaged in the discovery and development of innovative treatments for human infectious diseases. Idenix?s main focus is to advance the anti-viral pharmaceutical market. For more information about Idenix, visit: http://www.idenix.com/index.html.
ImQuest BioSciences
ImQuest Biosciences provides contract services for microbicide developers, including in vitro efficacy screening assays, in vitro efficacy evaluation against clinically-relevant strains of virus and cell types, cellular toxicity evaluation and toxicity to vaginal tissues, mechanism of topical microbicide action, range of action evaluations, combination assays with other potential topical microbicides, resistance evaluations, virus transmission inhibition evaluation, cervical explant and other ex vivo models, activity in candidate gel formulations, and animal models. For more information about ImQuest, visit: http://www.imquest.com/topical-microbicide.shtml.
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals focuses on the acquisition, development, and commercialization of innovative biopharmaceutical products. Indevus? portfolio includes compounds for the prevention of infection by HIV and other sexually transmitted pathogens. For more information about Indevus, visit: http://www.interneuron.com/.
Mapp Biopharmaceutical, Inc.
Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in public health and biodefense. For more information about Mapp Biopharmaceutical, visit: http://www.mappbio.com/.
Osel, Inc.
Osel works to commercialize pharmaceutical products utilizing naturally occurring bacteria in the maintenance of health and the prevention of disease. Osel?s mission is to harness the therapeutic properties of non-pathogenic bacteria as the basis for a series of innovative products targeted for the prevention and treatment of diseases of the genitourinary and gastrointestinal tracts. Osel is pursuing an innovative strategy to prevent the transmission of viral diseases in humans. For more information about Osel, visit: http://oselinc.com/index.php.
Polydex Pharmaceuticals Limited
Polydex maintains several active research programs in close collaboration with supportive industry partners internationally. Its lead human product, an innovative contraceptive prophylactic, is currently conducting late stage Phase 2 and 3 clinical trials to determine effectiveness at preventing pregnancy, HIV, and other sexually transmitted diseases. For more information about Polydex, visit: http://www.polydex.com/v2/home.html.
ReProtect, Inc.
ReProtect's mission is to reduce unwanted pregnancies and sexually transmitted diseases (STDs), including HIV/AIDS, by providing the most effective and innovative products to protect the reproductive health of women and men throughout the world. For more information about ReProtect, visit: http://www.reprotect.com/index.shtml.
